Spotlight on the July 7 Issue

#### Notable in Neurology This issue features articles discussing the gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis and altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Another featured article focuses on ADCY5 mutations as another cause of benign hereditary chorea. ### Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS![Graphic][1]![Graphic][2]![Graphic][3] Starting fingolimod 8–12 weeks after the last natalizumab infusion, rather than at 16 weeks, leads to better control of disease activity both clinically and on monthly MRI. Better control of disease activity with shorter intervals outweighs the theoretical risk of additive … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif